patient visits, use of prescription medications, and missed school days in such children [1] [2] [3] . Although influenz is generally a self-limited respiratory tract illness in school-aged children, rarely its consequences may be severe. Influenza-associate encephalitis and deaths in previously healthy school-aged children have been increasingly recognized in recent years [4] [5] [6] [7] [8] .
Children shed influenz virus for longer periods of time than adults [9, 10] . This may facilitate the transmission of influenz virus, particularly within schools and families. Family studies of influenz transmission during the 1970s found children to be the main introducers of influenz into households during interpandemic periods [11] [12] [13] . Thus, vaccination of school-aged children, in addition to providing individual protection, may decrease the chances of spreading influenz to high-risk family members and close contacts. Many children 5 years and older are now recommended to receive annual influenz vaccination either because they have a high-risk medical condition, such as asthma, Figure 1 . Proportion of children with seropositive titers (у1:10) for each influenza vaccine antigen at baseline, by age: 5 years ( ), 6 years n p 55 ( ), 7 years ( ), and 8 years ( ). n p 50 n p 58 n p 59
or because they live with 1 or more persons at increased risk of influenz complications, including children !5 years old, adults 65 years and older, and persons of any age with certain chronic medical conditions [14] . As the recommendation to vaccinate all children 6 months through 4 years of age is implemented, the number of school-aged children who receive influenz vaccine each year is also expected to increase substantially. Currently, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend that children younger than 9 years who have never been vaccinated with influenz vaccine receive 2 doses of influenz vaccine the firs year they are vaccinated [14, 15] . This recommendation is based on the premise that a significan proportion of such children are immunologically naive to influenz virus infection and require 2 doses of inactivated influenz vaccine for an adequate immune response [10, 16, 17] . Although the scientifi support for 2 doses of vaccine in infants and young children has been established, the need for 2 doses of vaccine for adequate immunogenicity in older children is less certain, and few contemporary studies have evaluated this age group specificall . From a practical standpoint, delivering 2 doses of influenz vaccine before the influenz season is challenging [16] . Thus, we assessed the additional benefi derived from a second dose of trivalent inactivated influenz vaccine (TIV) in vaccine-naive 5-8-year-old children. A secondary aim was to describe and compare the safety profil after 1 and 2 doses of vaccine. The study protocol was approved by the GHC and CDC institutional review boards, and informed consent was obtained from a parent or guardian of all study participants.
SUBJECTS, MATERIALS, AND METHODS

Study
Study subjects. Children who were enrolled in GHC since birth, had no record of influenz vaccination in the GHC immunization registry, and would be 5-8 years old at the time of the firs vaccination were invited to participate. Children were enrolled if parents gave informed consent, planned to be available for all study visits, and had telephone access. Subjects with acute febrile illnesses were eligible for enrollment, but vaccination was deferred for 24 h after the last oral temperature 138.0ЊC. Children were excluded from enrollment if there was a history of active cancer; an immunocompromising illness or current receipt of immunosuppressive agents; previous receipt of influenz vaccine of any kind; or allergy to eggs, egg products, or any other component of influenz vaccine. Prospective evaluation of reactogenicity was obtained using a parental diary. Parents were requested to record daily temperatures and any local reactions (pain, itching, redness, or swelling at the site of TIV administration) on the day of vaccination and daily for the 4 days after vaccination. Parents were contacted by telephone between 1 and 4 days after vaccination to remind them to complete the study diary and return the diary cards.
Laboratory methods. Serum samples were stored frozen at Ϫ20ЊC or lower until analyzed at the CDC. HAI antibody titers were determined in duplicate, running all paired specimens in the same test. Before testing, serum samples were treated with receptor-destroying enzyme (RDE; Denke Seiken). To inactivate the RDE, samples were heated to 56ЊC for 30 min. After the treatment, the serum samples were diluted to 1:10 and were then subjected to 2-fold serial dilutions. suspension of turkey red blood cells was then added to the mixture [18] .
Immunogenicity analysis. The proportions of subjects with a protective antibody response (у1:40) and the geometric mean titers (GMTs) of HAI antibodies were determined for each antigen after each vaccine dose by age and baseline antibody titer (!1:10, seronegative; у1:10, seropositive). After each dose, GMTs and the proportions of children with a protective antibody response were compared between age groups and between baseline antibody titer groups by use of t tests and x 2 tests, respectively. GMTs and proportions were compared after dose 1 versus dose 2 by use of a paired t test and McNemar's test, respectively. To assess the multivariate effects that dose, age (5-6 vs. 7-8 years), sex, and baseline serostatus have on protective antibody response, relative risk regression was used. Specificall , we modeled the probability of a protective response as an exponential function of risk factors and performed nonlinear least squares estimation to obtain asymptotically unbiased estimates of the relative risk of a protective response. To account for misspecificatio of the variance and the correlation between observations for the same participant after dose 1 and dose 2, we computed model-robust (Huber-White) SEs and performed estimation using generalized estimating equation (GEE) methodology. We did not use a logistic regression function because the prevalence of a protective response is not rare, and the odds ratios obtained from logistic regression models will overestimate the relative risk except when the relative risk is zero [19] . Similarly, multivariate linear regression was used to model the GMTs as a function of dose, age, sex, and baseline serostatus. Estimation was performed using GEE, and model-robust SEs were computed to account for correlation between measures on the same participant after dose 1 and dose 2.
Safety analysis. The proportions of subjects with solicited adverse events of any severity were determined for each age and baseline antibody titer group after each dose. Analyses were primarily descriptive; however, we compared the proportions of children with any fever, local reaction, or moderate/severe pain after dose 1 with the proportions of children with such reactions after dose 2, by use of McNemar's test. Additionally, after each dose, the proportions of children with local reactions or moderate/severe pain were compared between age groups and between seronegative and seropositive children, by use of x 2 tests. Finally, relative risk regression was used to assess the joint effects that sex, age, and baseline titer have on the probability of any pain or of moderate/severe pain. Separate regression models were developed for such reactions after each dose.
RESULTS
A total of 280 children were enrolled in the study; 17 dropped out after consent but before the firs vaccine dose, 31 dropped out after dose 1 but before dose 2, and 9 dropped out after receiving both vaccine doses but before the third blood draw. One child received both doses of vaccine but did not have a firs blood sample obtained. Thus, 222 children who received 2 doses of TIV and had 3 blood samples available were included in our fina immunogenicity analyses. Study diaries were returned after each dose for all 232 children who received 2 doses of TIV, and all 232 children were included in our fina safety analyses.
The mean age of the 222 children at the time of firs vaccine dose was 6.5 years, and 57% were male. Before the receipt of influenz vaccine, the proportions of children who were se- ropositive (HAI titer у1:10) for A/H1N1, A/H3N2, and B vaccine antigens were 54%, 91%, and 30%, respectively. The proportion of children seropositive for vaccine antigens at baseline increased with increasing age (figu e 1). The proportion of children with protective antibody responses (у1:40) after the firs and second doses of vaccine are shown in table 1. The effect that dose had on protective antibody response differed significantl by baseline serostatus. Among children who were seronegative at baseline, the antibody responses were low after 1 TIV dose, whereas, among children who were seropositive at baseline, 95%, 100%, and 100% achieved protective antibody responses to A/H1N1, A/H3N2, and type B vaccine antigens, respectively, after only 1 dose.
In multivariate analysis adjusting for age, sex, number of doses, and baseline serostatus, among all children combined, the proportion with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen ( , for A/H1N1; , for A/H3N2; P ! .001, P ! .001 P p .01 for B). Likewise, a positive baseline titer to a specifi antigen was significantl associated with the development of a protective antibody response to that antigen ( , for all 3 an-P ! .001 tigens) (figu e 2). After adjusting for baseline titer, neither age nor sex was independently predictive of a protective antibody response.
When antibody response was assessed by GMTs, results were similar, with high GMTs after 1 dose of vaccine in the seropositive group and low GMTs in the seronegative group (table  2) . Although a second dose of vaccine significantl increased GMTs for the strains included in the vaccine in seronegative children, there were no significan increases in HAI GMTs after the second dose in seropositive children. Moreover, children who were seropositive at baseline had significantl higher HAI GMTs after receiving 1 dose of vaccine than did children who were seronegative at baseline after receiving 2 doses of vaccine. For both seronegative and seropositive children, HAI GMTs were significantl lower for the B vaccine component, than for the A components. Antibody responses to the B/Hong Kong strain not contained in this year's vaccine were uniformly poor (tables 1 and 2). Influenz vaccine was well tolerated in all age groups and after both doses (table 3) . There were no significan differences in the proportion of children who had redness, swelling, fever, or itching after dose 1 than after dose 2. The proportions of children with any pain and with moderate/severe pain were significantl higher after dose 2 ( and , Mc-P p .002 P ! .001 Nemar's test, respectively). These differences were driven by differences in the older age groups (5-6-year-olds:
, for P p .08 any pain;
, for moderate/severe pain; 7-8-year-olds: P p .12 , for any pain;
, for moderate/severe pain). No P p .017 P ! .001 child reported pain beyond day 3 after vaccination. After ad- NOTE. Moderate indicates that the symptom causes some interference with daily activities (itching: treatment with cold packs or over-the-counter medication is used; pain: child protests to touch/has pain with arm movement). Severe indicates that the symptom is incapacitating (itching: child is unable to sleep or do usual activities; pain: child resists arm movement/keeps arm immobile).
justment for sex, age, and prevaccination titer for each antigen before vaccine, there were no significan predictors of any pain or of moderate/severe pain after dose 1. After dose 2, there were no significan predictors of any pain, but a prevaccination B/Jilin/20/2003 antibody titer у1:10 was predictive of moderate/severe pain (relative risk, 1.60 [95% confidenc interval {CI}, 1.01-2.56], compared with a titer !1:10).
DISCUSSION
Recommendations for the appropriate use of TIV in children are based principally on the results of large multicenter trials of monovalent and bivalent influenz vaccines conducted in the 1970s [10, 14, 20, 21] . Influenz vaccines have changed considerably since that time. Current US-licensed influenz vaccines are trivalent, contain 15 mg of each antigen, and are exclusively subvirion products. This prospective clinical study is, to our knowledge, the firs to compare the immunogenicity and reactogenicity of 1 versus 2 doses of modern TIV in this age group and affi ms the recommendations of the ACIP and AAP for 2 doses of TIV in children younger than 9 years of age receiving influenz vaccine for the firs time.
The strongest predictor of antibody response after a single dose of TIV was influenza-antige serostatus at baseline. The primary benefi derived from the second dose of vaccine was to increase the proportion of seronegative children who achieved a protective antibody response. In this study, among initially seronegative children, an additional 50%, 51%, and 31% developed protective responses to the A/H1N1, A/H3N2, and B antigens, respectively, after the second TIV dose. In the subset of children who were seropositive at baseline, the second dose of vaccine did not increase the antibody levels over those achieved after the firs dose (table 2) . Unfortunately, there is no practical way to identify the serostatus of children when they present for vaccination. Age is correlated with baseline antibody titer, but this correlation is not strong enough to be a clinically useful surrogate. For example, even among the 8-year-olds in this cohort, 35% were seronegative for A/H1N1 and 150% were seronegative for B at baseline. In contrast, among all ages, only 9% of children were seronegative for A/ H3N2 at baseline. These data reflec that A/H3N2 has been the predominant circulating influenz strain in the United States for the past 5-8 years, which represents the lifetime of these children [14] . Our study sample from a West Coast health maintenance organization may not be generalizable to all children in the United States, because influenz attack rates and circulation of types and subtypes of influenz viruses can vary substantially from community to community in a given season and from season to season. In addition, children in low-income settings may have greater exposure to respiratory viruses at a younger age, which might increase the proportion of such children who are seropositive for influenz antigens by a given age [22] .
Although we did not study vaccine efficac , the correlation between level of virus-specifi antibody titers and degree of protection is well established for influenz [23] [24] [25] [26] . It would be expected that the improved antibody responses observed in children after 1 or 2 doses of TIV will lead to improved protection, and a recent study of the effectiveness of 1 versus 2 doses of TIV in children 6 months to 8 years old supports our results [27] . In addition, studies of influenz outbreaks among children demonstrate that, at any given antibody level, protection after natural infection may be superior to protection after immunization with TIV [24] . In the present study, children who were seropositive at baseline had significantl higher GMTs after receiving 1 dose of vaccine than did children who were seronegative at baseline after receiving 2 doses of vaccine, suggesting that priming with natural infection may be superior to priming with TIV.
Over one-third of the children in this study had HAI antibody responses !1:40 for the B antigen, even after 2 doses of vaccine. The lower antibody responses to the B vaccine antigen, compared with those to the A vaccine antigens, are consistent with the findng of other studies [16, 28] . Although the lower antibody responses may be due to a reduced immunogencitiy of the B antigen component, it is also possible that measuring serologic responses to influenz B virus by HAI may be less sensitive than measuring neutralizing antibody [23, 29] . Gruber et al. administered a single dose of TIV to 6-9-year-old children and demonstrated protection against subsequent, laboratoryconfi med influenz B virus infection. Protection correlated with influenz B neutralizing antibody response [23] . Thus, it is possible that HAI antibody responses to influenz B virus [30] . The degree of immunity within an influenz virus subtype is dependent on the antigenic relatedness between the variants. As might be expected, TIV induced poor antibody responses to influenz B/Hong Kong, which represents a lineage distinct from that of the vaccine virus strain.
The live attenuated influenz vaccine (LAIV) is licensed in the United States for children 5 years and older. In a community effectiveness study, children 5-9 years of age who received a single dose of LAIV had significantl fewer episodes of medically attended acute respiratory tract illness, compared with LAIV nonrecipients in the intervention community. However, direct comparisons with the data in the present study are limited, because immunogenicity data were not collected as part of the LAIV study, and therefore the proportion of children who had prior exposure to influenz virus through natural infection or prior vaccination was not known [31] . Furthermore, serum antibody response may not be the best or only correlate of protection against influenz after receipt of LAIV [32] . Direct comparisons of LAIV and TIV are needed.
Our data provide additional evidence that influenz vaccines are well tolerated in children [16, [33] [34] [35] . Fever in the 5-day period after vaccination was rare, occurring in !1% of children. Injection-site pain, the most commonly reported adverse event, was significantl increased after the second dose of vaccine. In a prior study of 54 children 3-19 years of age receiving a firs dose of TIV, 20% reported tenderness at the site of injection that did not limit function, which is much lower than the 59% who reported injection-site pain in this study [23] . The reasons for the more frequent reports of pain in this study are uncertain but may be due to different methods of pain ascertainment, the ages of children, or vaccine antigen components. The proportion of children with pain reported in this study was similar to the proportion of children with pain after other vaccines administered to this age group [36] .
These results demonstrate clear immunogenicity benefit of a 2-dose TIV regimen in vaccine-naive 5-8-year-old children when all antigens are considered. Recent vaccine shortages, delays, and prioritization of high-risk groups for early vaccination will challenge the delivery of 2 doses of TIV to healthy 5-8-year-old children and to younger children. [37] . Although the majority of children in this study had preexisting antibody to H3N2, the pattern of circulation for H3N2 and other types and subtypes of influenz virus cannot be predicted, and the degree of exposure may vary for children in different regions. Thus, the 2-dose regimen remains the best strategy to prevent influenz illness in young children. More resources should be devoted to improving implementation of the 2-dose regimen for previously unvaccinated children !9 years of age.
